Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-07 Sale | 2024-03-08 5:31 pm | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 7,137 | $46.28 | $330,290 | 8,398 (Direct) | View |
| 2022-08-31 Sale | 2022-09-02 4:27 pm | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 65,231 | $38.31 | $2,499,023 | 16,796 (Direct) | View |
| 2022-03-04 Sale | 2022-03-08 7:35 pm | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 21,710 | $30.5 | $662,208 | 17,232 (Direct) | View |
| 2021-05-28 Sale | 2021-06-01 4:11 pm | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 6,067 | $18.81 | $114,120 | 32,232 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-11 Option Award | 2024-03-12 6:35 pm | N/A 2034-03-10 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 65,000 | $0 | 65,000 (Direct) | View |
| 2024-03-07 Tax Withholding | 2024-03-08 5:31 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 1,504 | $45.96 | 8,398 (Direct) | View |
| 2024-03-07 Exercise | 2024-03-08 5:31 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 8,641 | $9.85 | 8,398 (Direct) | View |
| 2024-03-07 Exercise | 2024-03-08 5:31 pm | N/A 2024-03-11 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 8,641 | $0 | 8,398 (Direct) | View |
| 2023-12-29 Other | 2024-01-02 4:41 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 8,398 | $0 | 16,796 (Direct) | View |
| 2023-03-10 Option Award | 2023-03-14 4:46 pm | N/A 2033-03-09 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 75,000 | $0 | 75,000 (Direct) | View |
| 2022-08-31 Tax Withholding | 2022-09-02 4:27 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 1,572 | $37.86 | 16,796 (Direct) | View |
| 2022-08-31 Exercise | 2022-09-02 4:27 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 55,000 | $4.75 | 16,796 (Direct) | View |
| 2022-09-01 Tax Withholding | 2022-09-02 4:27 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 6,121 | $38.81 | 16,796 (Direct) | View |
| 2022-08-31 Exercise | 2022-09-02 4:27 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 17,488 | $2.67 | 16,796 (Direct) | View |
| 2022-08-31 Exercise | 2022-09-02 4:27 pm | N/A 2022-12-31 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 72,488 | $0 | 16,796 (Direct) | View |
| 2022-03-10 Option Award | 2022-03-14 4:21 pm | N/A 2032-03-09 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 75,000 | $0 | 75,000 (Direct) | View |
| 2022-03-04 Exercise | 2022-03-08 7:35 pm | N/A 2022-03-10 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 7,406 | $0 | 17,232 (Direct) | View |
| 2022-03-04 Tax Withholding | 2022-03-08 7:35 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 696 | $31.42 | 17,232 (Direct) | View |
| 2022-03-04 Exercise | 2022-03-08 7:35 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 7,406 | $3.67 | 17,232 (Direct) | View |
| 2021-05-28 Tax Withholding | 2021-06-01 4:11 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 4,216 | $18.91 | 32,232 (Direct) | View |
| 2021-05-28 Exercise | 2021-06-01 4:11 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 12,345 | $3.76 | 32,232 (Direct) | View |
| 2021-05-28 Exercise | 2021-06-01 4:11 pm | N/A 2021-05-28 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 25,719 | $0 | 32,232 (Direct) | View |
| 2021-05-28 Exercise | 2021-06-01 4:11 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 13,374 | $3.85 | 32,232 (Direct) | View |
| 2021-03-12 Option Award | 2021-03-15 4:43 pm | N/A 2031-03-11 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 65,000 | $0 | 65,000 (Direct) | View |
| 2020-06-01 Exercise | 2020-06-02 5:40 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 8,230 | $3.56 | 16,796 (Direct) | View |
| 2020-06-01 Tax Withholding | 2020-06-02 5:40 pm | N/A N/A | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 1,630 | $13.7 | 16,796 (Direct) | View |
| 2020-06-01 Exercise | 2020-06-02 5:40 pm | N/A 2020-06-02 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 8,230 | $0 | 16,796 (Direct) | View |
| 2020-03-12 Option Award | 2020-03-13 5:09 pm | N/A 2030-03-11 | Xenon Pharmaceuticals Inc. | XENE | ROBIN SHERRINGTON EVP, Strategy & Innovation | 65,000 | $0 | 65,000 (Direct) | View |